Metrics to compare | SPRC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSPRCPeersSector | |
|---|---|---|---|---|
P/E Ratio | 4.5x | 37.2x | −0.4x | |
PEG Ratio | 0.01 | −0.41 | 0.00 | |
Price/Book | 5.2x | 1.4x | 2.6x | |
Price / LTM Sales | 3.7x | 1.3x | 3.1x | |
Upside (Analyst Target) | - | 11.9% | 48.8% | |
Fair Value Upside | Unlock | 9.3% | 5.7% | Unlock |
Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. It develops Sezaby, a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium injection for the treatment of neonatal seizures; SPARC-121, a novel topical agent for the treatment of Alopecia Areata; and SPARC-122, an anti-MUC1 ADC for treatment of multiple cancer indications. The company is also involved in the development of PDP-716 for treatment of open-angle glaucoma. Sun Pharma Advanced Research Company Limited was incorporated in 2006 and is based in Mumbai, India.